Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Infliximab
DATE: 23/06/2014
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
